Three Bridge Wealth Advisors LLC Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

Three Bridge Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 12,558 shares of the company’s stock after buying an additional 150 shares during the period. Three Bridge Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,080,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in NVO. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $42,000. Albion Financial Group UT boosted its holdings in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC increased its holdings in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $46,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on NVO. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $81.78 on Thursday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company’s 50 day simple moving average is $90.45 and its 200 day simple moving average is $110.60. The company has a market capitalization of $366.99 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 0.96 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is currently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.